Biovica International AB (publ) (STO:BIOVIC.B)
Sweden
· Delayed Price · Currency is SEK 0.291
+0.016 (5.82%)
Mar 9, 2026, 5:01 PM CET
Biovica International AB Revenue
Biovica International AB had revenue of 2.68M SEK in the quarter ending October 31, 2025, with 15.74% growth. This brings the company's revenue in the last twelve months to 9.89M, up 41.22% year-over-year. In the fiscal year ending April 30, 2025, Biovica International AB had annual revenue of 8.65M with 18.53% growth.
Revenue (ttm)
9.89M
Revenue Growth
+41.22%
P/S Ratio
8.59
Revenue / Employee
412.13K
Employees
24
Market Cap
84.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 8.65M | 1.35M | 18.53% |
| Apr 30, 2024 | 7.30M | 2.08M | 39.99% |
| Apr 30, 2023 | 5.21M | 113.00K | 2.22% |
| Apr 30, 2022 | 5.10M | -2.38M | -31.84% |
| Apr 30, 2021 | 7.48M | -2.20M | -22.71% |
| Apr 30, 2020 | Pro | Pro | Pro |
| Apr 30, 2019 | Pro | Pro | Pro |
| Apr 30, 2018 | Pro | Pro | Pro |
| Apr 30, 2017 | Pro | Pro | Pro |
| Apr 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Spago Nanomedical AB | 4.82M |
| Scandinavian ChemoTech AB | 12.29M |
| OncoZenge AB | 2.78M |
| Biosergen AB | 2.09M |
| Alligator Bioscience AB | 4.42M |
| Alzinova AB | 26.12M |
| Pila Pharma AB | 1.13M |
| Xbrane Biopharma AB | 152.35M |